Skip to main contentSkip to navigationSkip to search



Minimizing environmental footprint

Camurus strives to conduct a sustainable business where environmental and climate considerations are integrated into the company’s decisions. Together with suppliers and other stakeholders, the company works to minimize its operational and product-related impact throughout the entire value chain. This includes the development of circular solutions and avoiding incidents with impact on the environment.

Material aspects

Climate change

Camurus’ greatest climate impact is in scope 3 (estimated close to 80 percent), which is the emissions that occur upstream and downstream in the value chain. We actively work to minimize the company’s greenhouse gas emissions throughout the value chain. In 2023, an environmental mapping of the value chain was initiated with the aim of calculate and reduce the company’s impact, a work that continues in 2024.

Environmental impact (incl. pharmaceuticals in the environment

We strive to minimize the environmental impact of our products as much as possible, both related to water consumption, waste, use of resources and chemicals, energy flows etc. At Camurus, we work closely with our contract manufacturer to prevent the release of pharmaceuticals into soil or water.

Our goals

  • Reduce scope 1 and 2greenhouse gas emissions by at least 50%2 by 2035 
  • Reduce selected scope 33 greenhouse gas emissions by at least 40%2 by 2035 
  • Net zero greenhouse gas emissions (scope 1, 2 and 3) by 2045
  • From 2024 onwards, at least 80% of the energy used within Camurus’ operations to come from renewable sources
  • Transition from combustion engine cars to electric cars should be conducted as fast as possible5: From 2024 all new benefit cars are electric cars; Transition of job cars to electric cars in the Nordic countries by 2030; Transition of job cars to electric cars in other European countries by 2035; Transition of job cars to electric cars in all other countries by 2040

Transition plan

Camurus measures and is committed to reducing the company's emissions within Scope 1, 2 and 3. Learn about Camurus’ action plan for renewable energy and transition to climate neutrality

Climate impact in the value chain

To reduce Camurus’ total climate footprint in its own operations, production, distribution and use of medicines, Camurus has began to map and measure its climate impact according to the Greenhouse Gas Protocol standard.4) For 2023, Camurus reported data for scope 12) and 23) and partly for scope 35)An environmental mapping of Camurus’ full value chain is ongoing.

Our achievements

  • 95%

    share of renewable energy of total energy consumption*

Total scope 1 and 2 emissions by turnover (MSEK)**
Total scope 1 and 2 emissions by fulltime employee**

*as at end December 2023, source: Annual Report 2023.
**Company recalculation June 2024.
All emissions are reported in CO2 equivalents (CO2e).

2022 2023 
 Scope 1 tCO2e162,4 158,91 
 Scope 2 market based tCO2e11,32 17,43 
 Scope 2 location based tCO2e9,52 11,63 
 Scope 3 tCO2e60,3 385,64 

1. Reduced GHG emissions in scope 1 compared to 2022 due to the partial transition of company cars from combustion engine cars to electric cars. 
2. Camurus became aware of an error regarding the used emission factors for market placed and location based calculation in 2022. The 2022 scope 2 GHG emissions were recalculated. 
3. Increased GHG emissions in scope 2 compared to 2022 since the 2023 calculations include GHG emissions from the electric company car fleet and emissions from more offices.
4. Extended reporting of scop 3 emissions in 2023 compared to 2022. 2023 reporting includes emissions from the following categories: downstream transportation and distribution, purchased goods and services, and waste generated in own operations.

Reducing pharmaceuticals in the environment

Camurus strives to minimize the environmental impact of its products as much as possible and works closely with the company’s contract manufacturer to prevent the release of pharmaceuticals
into soil or water. Camurus’ products for e.g. the treatment of opioid dependence requires significantly lower amounts of active substance than comparable preparations for daily medication.

The contract manufacturer has well-developed safety procedures in place to prevent the release of pharmaceuticals, primarily from the active substance, into the environment. All process water is handled as hazardous waste and sent for disposal in accordance with applicable legislation, as well as contaminated containers and protective clothing.

In-depth data

For more in-depth data on focus area planet see Camurus' Annual Report 2023


  1. Scope 1 emissions include direct emissions from owned or controlled sources. Scope 2 emissions include indirect emissions from the generation of purchased energy. 
  2. Compared to 2023. 
  3. Scope 3 emissions include all indirect emissions (excluding scope 2) that occur in the company's supply chain, both upstream and downstream. 
  4. The remaining greenhouse gas emissions that cannot be reduced will be offset in 2045 and beyond. 
  5. Where technically feasible.